Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj

Koren, Sara

prikaz prve stranice dokumenta Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj

Download
PDF 415.22 KB

master's thesis

Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj

Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. urn:nbn:hr:163:385346

Koren, Sara

University of Zagreb
Faculty of Pharmacy and Biochemistry

Cite this document

APA 6th Edition

Koren, S. (2023). Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:385346

MLA 8th Edition

Koren, Sara. "Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:385346

Chicago 17th Edition

Harvard

Koren, S. (2023). 'Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 14 January 2025, https://urn.nsk.hr/urn:nbn:hr:163:385346

Vancouver

Koren S. Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2023 [cited 2025 January 14] Available at: https://urn.nsk.hr/urn:nbn:hr:163:385346

IEEE

S. Koren, "Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:163:385346

Cite this item: https://urn.nsk.hr/urn:nbn:hr:163:385346

Please login to the repository to save this object to your list.

Metadata

Title	Provođenje mjera minimizacije rizika primjene fluoropirimidina u Republici Hrvatskoj
Title (english)	Implementation of risk minimization measures for the use of fluoropyrimidines in the Republic of Croatia
Author	Sara Koren
Mentor	Nikica Mirošević Skvrce (mentor)
Mentor	Lana Ganoci (mentor)
Committee member	Nikica Mirošević Skvrce (predsjednik povjerenstva)
Committee member	Iva Mucalo (član povjerenstva)
Committee member	Lana Ganoci (član povjerenstva)
Granter	University of Zagreb Faculty of Pharmacy and Biochemistry Zagreb
Defense date and country	2023-11-24, Croatia
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Pharmacy Pharmacy
Abstract	Fluoropirimidini su skupina kemoterapeutika koji se koriste u liječenju više vrsta raka, a uključuju 5-fluorouracil te njegove oralne prolijekove kapecitabin i tegafur. U metabolizmu fluoropirimidina glavnu ulogu igra enzim dihidropirimidin-dehidrogenaza (DPD) koju kodira gen DPYD. Polimorfizmi i varijante gena DPYD povezuju se s nedostatkom aktivnosti enzima DPD te povećanim rizikom za razvoj teških nuspojava fluoropirimidina. Stoga je objavljeno je više smjernica koje daju preporuke za farmakogenetičko testiranje ovog gena. Cilj testiranja je otkriti moguće varijante gena DPYD prije terapije fluoropirimidinima te smanjiti rizik od nuspojava. Ovaj rad sadrži pregled metoda genotipizacije i fenotipizacije te sažetak najvažnijih nacionalnih smjernica država Europe i Europske agencije za lijekove (EMA). U sklopu ovog diplomskog rada, obrađeni su podaci farmakogenetičkog testiranja DPYD u pacijenata Republike Hrvatske u periodu od srpnja 2009. do lipnja 2023. godine. Prikazane su statistike o spolu i dobi pacijenata te broju testova provedenih svake godine. Obradom rezultata genotipizacije izračunate su frekvencije pojedinih varijanti u ispitivanoj populaciji te je prikazano podrijetlo preporuka za testiranje na razini primarne, sekundarne i tercijarne zdravstvene zaštite.
Abstract (english)	Fluoropyrimidines are a group of chemotherapeutic drugs used to treat a spectrum of carcinoma. The group includes 5-fluorouracil and its oral prodrugs capecitabine and tegafur. The enzyme dihydropyrimidine dehydrogenase, coded by the DPYD gene, has a major role in the metabolism of fluoropyrimidines. DPYD polymorphisms and variants are associated with lack of DPD enzyme activity and increased risk for development of fluoropirimidine severe adverse reactions. Therefore, several guidelines for DPYD testing have been published. The goal of these tests is to detect possible variants of the DPYD gene pre-treatment and to minimise the risk of side effects. This paper includes an overview of different genotyping and phenotyping methods, as well as an overview of the most important national guidelines of European countries and the European Medicines Agency (EMA). In this master's thesis, the results of more than a decade's worth of pharmacogenetic testing of DPYD in patients from the Republic of Croatia are presented. This paper shows the analysis of patients' sex and age and the number of tests performed each year. Included is the calculated frequency of each of the gene variant and the origin of testing recommendations at the primary, secondary and tertiary health care levels.
Keywords
Keywords (english)
Language	croatian
URN:NBN	urn:nbn:hr:163:385346
Study programme	Title: Pharmacy Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resource	Text
File origin	Born digital
Access conditions	Open access
Terms of use
Repository	Repository of Faculty of Pharmacy and Biochemistry University of Zagreb
Created on	2024-01-25 14:12:15